Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice

Abstract
This study tests the hypothesis that an Onchocerca volvulus vaccine, consisting of two recombinant antigens (Ov-103 and Ov-RAL-2) formulated with the combination-adjuvant Advax-2, can induce protective immunity in genetically diverse Collaborative Cross recombinant inbred intercross mice (CC-RIX). CC-RIX lines were immunized with the O. volvulus vaccine and challenged with third-stage larvae. Equal and significant reductions in parasite survival were observed in 7 of 8 CC-RIX lines. Innate protective immunity was seen in the single CC-RIX line that did not demonstrate protective adaptive immunity. Analysis of a wide array of immune factors showed that each line of mice have a unique set of immune responses to vaccination and challenge suggesting that the vaccine is polyfunctional, inducing different equally-protective sets of immune responses based on the genetic background of the immunized host. Vaccine efficacy in genetically diverse mice suggests that it will also be effective in genetically complex human populations.
Funding Information
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI078314, R01 AI078314, R01 AI078314, HHS-N272201400053C, HHS-N272200800039C, U01-AI061142, R01 AI078314, R01 AI078314, R01 AI078314, R01 AI078314)
  • UNC | UNC-Chapel Hill | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (MCR012CCRI)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA056036, P30 CA056036)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute